Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis

Published:2023-09 Issue: Volume: Page:101628
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Akhtar Othman Salim,Sheeba Ba Aqeel,Azad Farhan,Alessi Lauren,Hansen Doris,Alsina Melissa,Baz Rachid,Shain Kenneth,Grajales Cruz Ariel,Castaneda Puglianini Omar,Liu Hien,Blue Brandon,Nishihori Taiga,Al Jumayli Mohammed,Extermann Martine,Locke Frederick L.,Mhaskar Rahul,Freeman Ciara Louise

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference31 articles.

1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021

2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021

3. SEER cancer stat facts: Myeloma. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/mulmy.html (accessed 3/10/2023).

4. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up;Martin;J Clin Oncol.,2023

5. Efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis;Berdeja;Blood,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective;Current Oncology;2024-07-06

2. Zelluläre Therapien im Alter: Everything, everywhere, all at once?;InFo Hämatologie + Onkologie;2024-07

3. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma;American Society of Clinical Oncology Educational Book;2024-06

4. Personalized Treatment of Multiple Myeloma in Frail Patients;Current Oncology Reports;2024-05-18

5. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy;Transplantation and Cellular Therapy;2024-05